The Race to Speed Up the Effects of Cannabis
October 15th, 2018
Exclusive, Feature Stories, News
The cannabis industry is heating up with the legalization of medical and recreational cannabis across Canada and a growing number of states. While cannabis flower has been the early focus, cannabinoid-infused edibles and concentrates represent the fastest growing segments of the $100+ billion industry.
Absorption is one of the most important differentiators for both medical and recreational cannabis products. Medical cannabis patients want to receive a standardized dose and consistent effect each time, while recreational consumers want to experience a high as quickly as possible.
Lexaria Biosciences Inc. (OTCQX: LXRP) (CSE: LXX) has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits.
“We are focused on making ingestible or edible bioactive substances taste better, smell better, act faster and enhance potency,” says Lexaria President John Docherty, a trained pharmacologist and toxicologist, who is also the former president and chief operation officer of Helix BioPharma Corp.
Internal R&D vs. Outsourcing
Many cannabis companies plan to launch cannabis-infused products over the coming year. In fact, the alcohol industry has been so concerned about the potential for these products that giants like Constellation Brands Inc. (NYSE: STZ) and Molson Coors Brewing Co. (NYSE: TAP) have made significant investments.
With the race to develop alternative cannabis products, many cannabis companies have a choice between developing internal delivery platforms or partnering with experts to develop top-performing products. Internal develop involves a high cost and potentially lengthy delays but provides flexibility, while partnerships can provide speed to market and a known solution at a predetermined cost.
Lexaria Biosciences’ innovative drug delivery platform enables cannabis absorption in just 10 to 20 minutes compared to the 60 to 120 minutes for many cannabis edibles on the shelves today. The technology also represents an alternative to sugars and chemicals that are often used to mask flavors. Lexaria was one of the first to offer these solutions to the cannabis industry.
The company has already licensed its products to numerous cannabis companies. For example, the company’s customers include the maker of the 1906 brand of cannabis-infused chocolates in Colorado, a Canadian-based developer of cannabis wines and beers, and a new Canadian company focused on cannabis-infused edibles.
Clinically Proven Advantages
Lexaria’s DehydraTECH platform has shown tremendous promise in several different clinical studies. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the earthy taste of cannabis and delivers it more effectively.
Earlier this year, the company released the results of a randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD—a proprietary DehydraTECH powered CBD hemp oil capsule—showing 317% greater absorption at the 30 minute mark and higher blood concentration. Lexaria is one of very few companies anywhere in the world to have completed human clinical studies related to cannabinoids and have proven that its technology is effective.
The company conducted similar studies of DehyraTECH’s potential with other active ingredients, such as nicotine. In an in-vivo animal study, researchers delivered DehydraTECH powered nicotine in an edible form into blood plasma in just minutes after dosing with 90.2 percent greater delivery than control after just 10 minutes. Lexaria is one of the only companies in the world with technology proven effective in both the nicotine and cannabis industries.
Lexaria’s growing portfolio of more than 50 patents has expanded its drug delivery platform well beyond cannabis, including vitamins, NSAIDs, nicotine, and other molecules. Management plans to develop the patent portfolio into 150 to 200 patent applications around the world within two years.
Investors interested in capitalizing on the burgeoning cannabis industry along with additional potential across other multi-billion dollar markets may want to take a closer look at the company ahead of further partnerships and announcements.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.